AN2 Therapeutics, Inc. also appointed two additional members to its Board of Directors, Patricia Martin and Stephanie Wong. Currently, Ms. Wong serves as Chief Financial Officer and Secretary of Calithera Biosciences. A former Eli Lilly and Company executive, Ms. Martin was the Chief Operating Officer of Lilly Diabetes as well as Lilly's corporate Chief Diversity Officer and Chief Alliance Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.72 USD | +7.51% | +6.67% | -86.73% |
07-05 | Leerink Upgrades AN2 Therapeutics to Outperform Rating With $5 Price Target | MT |
07-03 | Leerink Partners Upgrades AN2 Therapeutics to Outperform From Market Perform, Price Target is $5 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.73% | 75.47M | |
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |
- Stock Market
- Equities
- ANTX Stock
- News AN2 Therapeutics, Inc.
- AN2 Therapeutics, Inc. Appoints Patricia Martin and Stephanie Wong to the Board of Directors